Find Oncology Drugs in Phase II/III Clinical Development in GERMANY

Lead Product(s): Tafasitamab

Therapeutic Area: Oncology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Incyte

Deal Size: $2,000 million Upfront Cash: $750.0 million

Deal Type: Collaboration January 13, 2020

Details:

MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.